Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

... and was Well Tolerated When Given With Standard platelet Therapy KENILWORTH, N.J., March 12 ... thrombin-receptor agonist peptide (TRAP)-induced platelet aggregation inhibition, a secondary endpoint. Thrombin is the most potent platelet activator, which leads ...

Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

... First and Only Approved platelet Producer in Europe Represents New Treatment ... Nplate, the first and only approved platelet producer in Europe, has been granted marketing ... 2008. Nplate works by raising and sustaining platelet counts, representing a novel approach for the ...

New Research Suggests Platelet 'Stickiness' May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease

... at Sinai Hospital of Baltimore, indicate that platelet aggregation or "stickiness" may be the single ... yet the pivotal event that kills the patient - platelet aggregation isn't being assessed in any way," ... never have a cardiac event because they had low platelet aggregation. Along with his team at Sinai, ...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... monitor complete blood count (including platelet count), at least prior to each dose of DOXIL ... sarcoma, hematologic toxicity (based on platelet count or absolute neutrophil count) ... hematologic toxicity (based on platelet count, absolute neutrophil count, hemoglobin ...

Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention

... agents through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable platelet inhibition in the chronic setting. Additionally, ... and demonstrated predictable, dose-dependent platelet inhibition. INNOVATE-PCI is designed to ...

Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients

... "These data show Nplate increased platelet counts in most patients for most of the time, and ... are at risk of serious bleeding events if their platelet counts drop to less than 30,000 per ... 74 percent of patients (160/215) achieved a platelet response defined as ...

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

... oral treatment for chronic ITP, a low-dose platelet transfusion strategy for patients with hypoproliferative thrombocytopenia, and a new therapeutic platelet transfusion approach following high-dose ... to minimize bleeding episodes in patients with platelet disorders," said press conference moderator ...

GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP

... more likely than those on placebo to maintain platelet counts between 50,000 to 400,000/microliters ... should not be used in an attempt to normalize platelet counts. Chronic ITP is a disorder marked by increased platelet destruction ...

Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union

... Phase 3 studies, demonstrating that platelet counts were raised and sustained in 83 percent of ... continued to effectively increase and sustain platelet counts. In this open label long term ... risk for serious bleeding events increases when platelet counts drop to less than 30,000 platelets ...

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder

... said Craig Conway, executive director of the platelet Disorder Support Association. "The approval of ... Shift in Approach "Preventing platelet destruction has always been the primary means of ... said James Bussel, M.D., director of the platelet Disorders Center, Children's Cancer and Blood ...

Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders

... PRT060128 Provides Reversible, High-level platelet Inhibition with Immediate Onset of ... a seamless transition to predictable, reversible platelet inhibition in the chronic setting. "Of the ... after the previous day's dose of clopidogrel. platelet aggregation was determined by ADP ...

Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel

... of previous studies that showed higher levels of platelet aggregation in insulin-treated diabetes ... undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking ... adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets ...

Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis

... inhibition of serotonin-mediated amplification of platelet aggregation was demonstrated starting at the 15 ... near-complete inhibition of serotonin-mediated platelet aggregation. These results further ... increased cardiovascular risk. Normally, when a platelet is activated by one of a number of factors, such ...

DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin

... crossover study compared the effects on platelet activation and bleeding time of DG041 alone and ... shown to offer a novel approach to inhibiting platelet aggregation where it is needed -- at the site of ... was shown to substantially inhibit EP3 mediated platelet activation that is not being addressed by current ...

Tailored Clopidogrel Dosing Improves PCI Outcomes

... "Tailoring the loading dose of clopidogrel using platelet monitoring seems to be the best way to decrease ... resistance was defined as more than 50 percent platelet activity after a standard 600-mg clopidogrel ... clopidogrel before PCI, and experienced a drop in platelet activity from 69.3 after the first loading dose ...

FDA Grants Priority Review for PROMACTA(R) (eltrombopag)

... treated patients with chronic ITP to increase platelet counts and reduce bleeding. "Our goal for ... in oral form for patients to help raise their platelet counts without having to suppress the immune ... Chronic ITP is a disorder marked by increased platelet destruction and/or ...

BioVascular Inc. Closes $10.87 Million Series C Financing

... trials. BVI-007, a compound that acts to reduce platelet production without affecting platelet function, is being studied in a Phase Ib dose ... platelets to those fibrils. By blocking platelet adhesion, saratin blocks the first step in a ...

Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial

... inhibition of serotonin-mediated amplification of platelet aggregation was demonstrated starting at the 1 ... increased cardiovascular risk. Normally, when a platelet is activated by one of a number of factors, such as thrombin or collagen, the platelet releases serotonin, which, based on preclinical ...

Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting

... purpura increased and maintained platelet counts at greater than or equal to ... study showed that of the patients with a baseline platelet count of less than 30,000/microliters, 73% ... results suggest that PROMACTA sustains increased platelet counts during long-term treatment.(1) This ...

SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients

... coronary intervention (PCI). "The inhibition of platelet aggregation plays a critical role in reducing the ... unique mechanism of action inhibits platelet aggregation through a different pathway from ... evaluable patient cohort was inhibition of platelet aggregation (IPA) induced by appropriate agonists ...

Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting

... INTEGRILIN(R) significantly decreased platelet aggregation in response to multiple stimuli, ... importance of a GP IIb-IIIa inhibitor in reducing platelet aggregation," said Paul Gurbel, MD, Director of ... study supports the role of inhibition of platelet aggregation in patients undergoing elective ...

Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies

... studies compare the levels of inhibition of platelet aggregation (IPA) in patients with coronary ... undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking ... adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets ...

Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation

... have identified the mechanism that accounts for platelet hyper-responsiveness during abnormal blood ... may be developed to prevent inappropriate platelet activation and reduce the risk of ... with abnormal cholesterol levels. Excessive platelet activation can lead to blood clot formation and ...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

... significant improvements compared with baselines were also observed in platelet and spleen sizes, and nominally significant improvements were observed in ... the 45 U/kg IV dose, statistically significant improvements in hemoglobin, platelet count, and spleen volume were also demonstrated. The magnitude of changes ...

Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled

... ) Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet ... industry-leading and widely accessible diagnostic tests for rapid platelet function assessment. Accumetrics' VerifyNow System is the first rapid ...

New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel

... acute coronary syndromes undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking ...

Schering-Plough Announces Results of the Early ACS Trial

... heparin should be stopped immediately; because INTEGRILIN inhibits platelet aggregation, caution should be employed when it is used with other drugs ... should be exercised when administering INTEGRILIN to patients with a platelet count <100,000/mm3. Bleeding is the most common complication ...

American Academy Of Orthopaedic Surgeons 2009 Annual Meeting 'Highlights and Hot Topics'

... surfacing. Growth factor combinations such as bone morphogenetic protein, platelet rich plasma, and platelet derived growth factor and other potential therapeutic agents are now being ...

Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel

... acute coronary syndromes undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking ...

ViaViente Demonstrates Cardiovascular Benefits in New Human Trial

... natural food product. It correlates the consumption of ViaViente to platelet inhibition -- a marker of CVD. Why is cardiovascular health so ... the production of thromboxane can help reduce vasoconstriction and platelet stickiness. Experts agree that there is a well established relationship ...

FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel

... Company, Limited. About Trilogy ACS The study, TRILOGY ACS (TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute ... coronary syndromes who are managed with PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine ...

Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial

... such as clopidogrel (Plavix(R)). These patients have a high degree of platelet reactivity and, as a result, are at greater risk of a major adverse ... industry-leading and widely accessible diagnostic tests for rapid platelet function assessment. VerifyNow is the first simple and rapid system for ...

Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... may occur; frequently monitor complete blood count (including platelet count), at least prior to each dose of DOXIL -- In patients with multiple myeloma, hematologic toxicity (based on platelet count, absolute neutrophil count, hemoglobin level, or ...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting

... Data Presentations at DDW PEGINTRON Results from the EPIC3 Program: platelet Counts Are Strong Predictors of Sustained Viral Response (SVR) in the ... 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative ...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting

... long-term clearance of HCV at 5-year follow-up. Manns, M. et al. platelet count predicts sustained viral response (SVR) in the retreatment of ... 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative ...

TRITON-TIMI 38 Stent Analysis Favors Prasugrel

... from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing platelet Inhibition with Prasugrel (TRITON-TIMI 38) reveals that the ... of the "Trial to Assess Improvement in Therapeutic Outcomes by Optimizing platelet Inhibition with Prasugrel" (TRITON-TIMI 38) stent substudy on Saturday, ...

Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial

... With A VerifyNow Assay-Impact On Thrombosis And Safety) to establish platelet function testing with VerifyNow as the standard of care. The Executive ... of the steady progress we've made focusing on surgical procedures where platelet function testing has immediate clinical relevance and gives us an ...

Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent

... the 20 patients (13CR/7PR) who were evaluable (at least a PR with normal platelet counts and bone marrow infiltration <25%) for subsequent Zevalin, 100% ... in 11 of 20 patients. Four patients received GCSF and 3 patients received platelet transfusions. Only 1 patient experience febrile neutropenia. The authors ...

Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)

... by their physician. Bleeding can occur at any site with LOVENOX(R) use. platelet drops, known as "thrombocytopenia," can occur with LOVENOX(R) use. Cases ... may perform blood tests to monitor for the occurrence of any drop in platelet count. The use of LOVENOX(R) has not been adequately studied in pregnant ...

Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting

... may occur; frequently monitor complete blood count (including platelet count), at least prior to each dose of DOXIL -- In patients with multiple myeloma, hematologic toxicity (based on platelet count, absolute neutrophil count, hemoglobin level, or neutropenia ...